Abstract
Diuretics play an essential role in modern cardiovascular therapy, and are currently recommended for the treatment of congestive heart failure. Torasemide has been developed as a newer type of loop diuretic with a longer halflife, longer duration of action, and higher bioavailability compared to the most commonly used loop diuretic, furosemide. Torasemide also appears to have additional actions beyond the pure diuretic effect, such as anti-aldosterone effect and vasorelaxation effect. Studies have also investigated whether the superior pharmacokinetics and pharmacological activity of torasemide result in a favorable clinical outcome. Their results have indicated that, in comparison with furosemide, torasemide improves left ventricular function, reduces mortality as well as the frequency and duration of heart failurerelated hospitalization, and improves quality of life, exercise tolerance and NYHA functional class in patients with congestive heart failure. Thus, torasemide appears to be a promising loop diuretic that contributes to a better management of patients with heart failure. Definitive clinical trials in a double-blind fashion are warranted.
Keywords: Diuretics, furosemide, heart Failure, torasemide
Cardiovascular & Hematological Disorders-Drug Targets
Title: Torasemide for the Treatment of Heart Failure
Volume: 8 Issue: 2
Author(s): Hirotaka Ishido and Hideaki Senzaki
Affiliation:
Keywords: Diuretics, furosemide, heart Failure, torasemide
Abstract: Diuretics play an essential role in modern cardiovascular therapy, and are currently recommended for the treatment of congestive heart failure. Torasemide has been developed as a newer type of loop diuretic with a longer halflife, longer duration of action, and higher bioavailability compared to the most commonly used loop diuretic, furosemide. Torasemide also appears to have additional actions beyond the pure diuretic effect, such as anti-aldosterone effect and vasorelaxation effect. Studies have also investigated whether the superior pharmacokinetics and pharmacological activity of torasemide result in a favorable clinical outcome. Their results have indicated that, in comparison with furosemide, torasemide improves left ventricular function, reduces mortality as well as the frequency and duration of heart failurerelated hospitalization, and improves quality of life, exercise tolerance and NYHA functional class in patients with congestive heart failure. Thus, torasemide appears to be a promising loop diuretic that contributes to a better management of patients with heart failure. Definitive clinical trials in a double-blind fashion are warranted.
Export Options
About this article
Cite this article as:
Ishido Hirotaka and Senzaki Hideaki, Torasemide for the Treatment of Heart Failure, Cardiovascular & Hematological Disorders-Drug Targets 2008; 8 (2) . https://dx.doi.org/10.2174/187152908784533685
DOI https://dx.doi.org/10.2174/187152908784533685 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pre and Post-Operative Treatments for Prevention of Atrial Fibrillation after Cardiac Surgery
Mini-Reviews in Medicinal Chemistry Acute Coronary Syndromes in Patients with Chronic Kidney Disease
Current Vascular Pharmacology Pleural Fluid Analysis for Evaluating Pleural Effusions
Current Respiratory Medicine Reviews Molecular Mechanisms of Mineralocorticoid Receptor Antagonism by Eplerenone
Mini-Reviews in Medicinal Chemistry P2X Receptors and Inflammation
Current Medicinal Chemistry The Role of Statins in the Activation of Heme Oxygenase-1 in Cardiovascular Diseases
Current Drug Targets Facing Up the ROS Labyrinth - Where To Go?
Current Vascular Pharmacology Transactivation of ErbB Receptors by Leptin in the Cardiovascular System: Mechanisms, Consequences and Target for Therapy
Current Pharmaceutical Design Angiotensin II and Abdominal Aortic Aneurysms: An update
Current Pharmaceutical Design Involvement of Intracellular pH in Vascular Insulin Resistance
Current Vascular Pharmacology Compritol<sup>®</sup>888 ATO a Lipid Excipient for Sustained Release of Highly Water Soluble Active: Formulation, Scale-up and IVIVC Study
Current Drug Delivery Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Radiopharmaceutical: Revolutionary Agents for Diagnosis
Current Radiopharmaceuticals Osteoprotegerin and Diabetes-Associated Pathologies
Current Molecular Medicine Crude Venom from Nematocysts of the Jellyfish Pelagia noctiluca as a Tool to Study Cell Physiology
Central Nervous System Agents in Medicinal Chemistry Current Advances in Clinical Trials for Rare Disease Populations: Spotlight on the Patient
Current Reviews in Clinical and Experimental Pharmacology Telmisartan in the Management of Diabetic Nephropathy: A Contemporary View
Current Diabetes Reviews Effects of Dietary Intake and Supplementation of Fatty Acids on Cardiometabolic Disorders in Humans: a Lesson from a Large Number of Meta-Analyses
Letters in Drug Design & Discovery A Historical Overview on Coronary Surgery and Interventional Cardiology: Parallel Pathways?
Vascular Disease Prevention (Discontinued) Pharmacological Characteristics and Clinical Applications of K201
Current Clinical Pharmacology